Safety and Durability of Sirolimus for Treatment of LAM
Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)
University of Cincinnati
600 participants
Mar 1, 2015
OBSERVATIONAL
Conditions
Summary
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Eligibility
Inclusion Criteria4
- Female or male, age 18 or over
- Diagnosis of LAM based on ATS/JRS criteria
- Signed and dated informed consent
- On chronic therapy, newly treated or may be considered for therapy with mTOR inhibitors or previously intolerant of or having failed mTOR inhibitor therapy
Exclusion Criteria3
- Inability to attend at least one RLD Clinic visit per year
- Inability to give informed consent
- Inability or unwillingness to perform pulmonary function testing
Interventions
Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
Locations(20)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02432560